About: Clinical study of Japanese spotted fever and its aggravating factors

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical study of Japanese spotted fever and its aggravating factors Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Clinical study of Japanese spotted fever and its aggravating factors
Creator	Senba, Takanori Chikahira, Y Chikahira, Yoshimi Kodama, K Kodama, Kazuya Nomura, Tetsuhiko Nomura, · Senba, T Yamauchi, Hayato Yamauchi, ·
source	PMC
abstract	Twenty-eight patients with Japanese spotted fever were clinically investigated. The diagnosis was determined by confirming an increase of specific antibody. All patients were treated with minocycline, and all recovered, excluding one patient with a fulminant course. Fever and exanthema were observed in all patients, and an eschar was pointed out in 20 (71%) patients. The platelet count was 10 × 10(4)/μl or lower in 8 (28%) patients. The fibrin degradation product (FDP)-level was abnormally high, 10 μg/ml or more, in 16 (57%) patients. The creatine kinase (CK) value was high in 14 of 22 patients, suggesting the presence of myositis. The leukocyte count, FDP, C-reactive protein, and soluble interleukin 2 receptor (sIL2-R) levels were significantly higher in severe cases. In the group without concomitant steroid therapy, mean times of 54.7 h and 101.4 h were required to reduce the temperature to 38°C and 37°C or lower, respectively, after the initiation of tetracycline treatment. There were 6 severe cases: 1 with disseminated intravascular coagulation, 2 with multiorgan failure, 1 with acute respiratory distress syndrome, and 2 with meningoencephalitis. These severe cases formed a group that required 6 or more days to initiate therapy after the onset (P < 0.005 vs non-severe group), showing that delay in diagnosis and therapy is the major cause of aggravation. In the 2 patients complicated by multiorgan failure, the sIL2-R level, produced by activated lymphocytes, was 10 000 U/ml or higher, suggesting that an sIL2-R level of more than 10 000 U/ml can be used as a marker of poor prognosis. It may be better that moderate to severe cases are treated with minocycline plus short-term steroid therapy.
has issue date	2003-01-01(xsd:dateTime)
bibo:doi	10.1007/s10156-002-0223-5
bibo:pmid	12673413
has license	no-cc
sha1sum (hex)	ad9e37880798b2ed836cdfea9113936540cf16d6
schema:url	https://doi.org/10.1007/s10156-002-0223-5
resource representing a document's title	Clinical study of Japanese spotted fever and its aggravating factors
has PubMed Central identifier	PMC7102015
has PubMed identifier	12673413
schema:publication	J Infect Chemother
resource representing a document's body	covid:ad9e37880798b2ed836cdfea9113936540cf16d6#body_text
is schema:about of	named entity 'patients' named entity 'antibody' named entity 'count' named entity 'diagnosis' named entity 'sIL2' named entity 'group' named entity 'produced' covid:arg/ad9e37880798b2ed836cdfea9113936540cf16d6 named entity 'cases' named entity 'temperature' named entity 'cases' named entity 'times' named entity 'The' named entity 'moderate' named entity 'cases' named entity 'FDP' named entity 'receptor' named entity 'patients' named entity 'therapy' named entity 'disseminated intravascular coagulation' named entity 'disseminated intravascular coagulation' named entity 'myositis' named entity 'FDP' named entity 'leukocyte count' named entity 'platelet count' named entity 'acute respiratory distress syndrome' named entity 'C-reactive protein' named entity 'fulminant' named entity 'short-term' named entity 'Fever' named entity 'Japanese spotted fever' named entity 'therapy' named entity 'receptor' named entity 'fever reduction' named entity 'JSF' named entity 'FDP' named entity 'disseminated intravascular coagulation' named entity 'case reports' named entity 'rickettsiosis' named entity 'platelet count' named entity 'rickettsiae' named entity 'pathological conditions' named entity '0.01' named entity 'fluorescent antibody' named entity 'PCR' named entity 'tick-borne' named entity 'steroid' named entity 'tumor necrosis factor-alpha' named entity 'cytokines' named entity 'fever' named entity 'minocycline' named entity 'lymphocytes' named entity 'lymphocytes' named entity 'platelet count' named entity 'mortality rate' named entity 'hemophagocytic syndrome' named entity 'antibody' named entity 'Fisher's exact test' named entity 'FDP' named entity 'fibrin degradation product' named entity 'multiorgan failure' named entity 'IgA' named entity 'antibiotic' named entity 'hemophagocytic syndrome' named entity 'physical examination' named entity 'steroids' named entity 'clinical features' named entity 'JSF' named entity 'enzyme' named entity 'Hypercytokinemia' named entity 'immunosuppression' named entity 'meningoencephalitis'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software